PUBLIC COMPANY
saveNOVO
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 1h ago
- STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and moreAn FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twicestat · 3h ago
- STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease studyA Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.stat · 4h ago
- Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 failA phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfol…fiercebiotech · 7h ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 1d ago
- Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapyElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.biospace · 2d ago
- 7 companies hiring in New York nowLooking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.biospace · 2d ago
- Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtShareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artific…biospace · 2d ago
- GSK cost-cutting plan includes global layoffsFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 2d ago
- Novo Nordisk fails to dismiss lawsuit over CagriSema readoutNovo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.fiercebiotech · 2d ago
comments(0)
5-min edit window · permanent after that